Tissue Regenix Group Past Earnings Performance
Past criteria checks 0/6
Tissue Regenix Group has been growing earnings at an average annual rate of 35%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 15.8% per year.
Key information
35.0%
Earnings growth rate
67.8%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 15.8% |
| Return on equity | -3.3% |
| Net Margin | -3.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Does Tissue Regenix Group (LON:TRX) Have A Healthy Balance Sheet?
Nov 02
Tissue Regenix Group plc's (LON:TRX) Share Price Is Matching Sentiment Around Its Revenues
Jun 01Tissue Regenix Group plc's (LON:TRX) Shares Bounce 25% But Its Business Still Trails The Industry
Feb 25Is Tissue Regenix Group (LON:TRX) A Risky Investment?
Jun 10Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?
Apr 02Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?
Nov 18
Revenue & Expenses Breakdown
How Tissue Regenix Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 32 | -1 | 15 | 0 |
| 31 Mar 24 | 31 | -1 | 15 | 0 |
| 31 Dec 23 | 29 | -2 | 14 | 0 |
| 30 Sep 23 | 28 | -2 | 14 | 0 |
| 30 Jun 23 | 27 | -2 | 14 | 0 |
| 31 Mar 23 | 26 | -2 | 14 | 0 |
| 31 Dec 22 | 24 | -3 | 13 | 0 |
| 30 Sep 22 | 23 | -3 | 13 | 0 |
| 30 Jun 22 | 22 | -4 | 13 | 0 |
| 31 Mar 22 | 21 | -4 | 13 | 0 |
| 31 Dec 21 | 20 | -5 | 12 | 0 |
| 30 Sep 21 | 19 | -8 | 12 | 0 |
| 30 Jun 21 | 18 | -12 | 12 | 0 |
| 31 Mar 21 | 17 | -12 | 12 | 0 |
| 31 Dec 20 | 16 | -12 | 13 | 0 |
| 30 Sep 20 | 17 | -10 | 12 | 1 |
| 30 Jun 20 | 16 | -7 | 11 | 2 |
| 31 Mar 20 | 16 | -8 | 12 | 2 |
| 31 Dec 19 | 17 | -9 | 14 | 2 |
| 30 Sep 19 | 15 | -9 | 13 | 2 |
| 30 Jun 19 | 15 | -10 | 14 | 2 |
| 31 Mar 19 | 15 | -10 | 15 | 2 |
| 31 Dec 18 | 15 | -10 | 15 | 2 |
| 30 Sep 18 | 14 | -11 | 15 | 2 |
| 30 Jun 18 | 12 | -12 | 15 | 2 |
| 31 Mar 18 | 10 | -13 | 15 | 2 |
| 31 Dec 17 | 7 | -12 | 14 | 2 |
| 31 Dec 16 | 2 | -13 | 14 | 2 |
| 31 Jul 16 | 2 | -14 | 12 | 5 |
| 30 Apr 16 | 1 | -15 | 12 | 5 |
| 31 Jan 16 | 1 | -13 | 10 | 5 |
| 31 Oct 15 | 1 | -13 | 10 | 5 |
| 31 Jul 15 | 1 | -12 | 9 | 5 |
| 30 Apr 15 | 0 | -12 | 8 | 5 |
| 31 Jan 15 | 0 | -11 | 8 | 5 |
| 31 Oct 14 | 0 | -12 | 8 | 5 |
| 31 Jul 14 | 0 | -12 | 8 | 6 |
| 30 Apr 14 | 0 | -11 | 7 | 6 |
| 31 Jan 14 | 0 | -9 | 5 | 6 |
Quality Earnings: TRX is currently unprofitable.
Growing Profit Margin: TRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TRX is unprofitable, but has reduced losses over the past 5 years at a rate of 35% per year.
Accelerating Growth: Unable to compare TRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Return on Equity
High ROE: TRX has a negative Return on Equity (-3.34%), as it is currently unprofitable.